Lyme Disease

Pic:getty/hailshadow

Pfizer invests $95m in Valneva

By Rachel Arthur

Pfizer will invest €90.5m ($95m) in French vaccine specialist Valneva, representing 8.1% of Valneva’s share capital. The investment will support the duo’s Lyme disease vaccine partnership.

Valneva-GSK sever vaccine alliance

GSK-Valneva end legacy vaccines partnership

By Ben Hargreaves

GSK and Valneva have come to a mutual early termination agreement, as the former looks to ‘allocate capital to fewer, highest priority areas’.

Spotlight

Follow us

Products

View more

Webinars

Featured Suppliers

All suppliers